2019-04-12

Exercise of over-allotment option, stabilisation notice and end of the stabilisation period

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Erik Penser Bank AB (publ) (”Erik Penser Bank”) notifies that stabilisation measures have been undertaken in Ascelia Pharma AB’s (publ) (”Ascelia Pharma” or the “Compa ...
2019-04-11

Stabilisation notice

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Erik Penser Bank AB (publ) (”Erik Penser Bank”) notifies that stabilisation measures have been undertaken in Ascelia Pharma AB’s (publ) (”Ascelia Pharma” or the “Company ...
2019-04-08

Encouraging results from the Phase I combination study with Oncoral and oral capecitabine published in the journal Cancer Chemotherapy and Pharmacology

Ascelia Pharma AB (ticker: ACE), announces results from the Phase I investigator-sponsored extension study (ClinicalTrials.gov Identifier: NCT03295084) demonstrating reassuring tolerability of the oral chemotherapy tablet Oncoral (oral irinotecan) administered in combination with oral capecitabine. These results are published in Cancer Chemotherapy and Pharmacology, a peer reviewed medical journal covering oncological pharmacotherapy.